AnteoTech Limited announced the appointments of two new independent Non-Executive Directors to the Company, Ms. Glenda McLoughlin and Dr. Katherine Woodthorpe effective 1 September 2021. In addition to the appointment of the two Non-Executive Directors, the Board announced the formation of two Advisory Boards with the appointment of Prof. Paul Young and Prof. Dominic Dwyer to the Clinical Advisory Board and Mr. Oliver Gross and Dr. Kevin Eberman to the Energy Advisory Board. Ms. Glenda McLaughlin is an experienced Non-Executive Director with over 25 years' experience as an Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. Ms. McLoughlin currently holds the positions of Non-Executive Director with Senex Energy Ltd. where she chairs the Audit and Risk Committee and is Chair of SCEGGS Redlands. Ms. McLoughlin will become Chair of AnteoTech's Audit and Risk Committee. Dr. Katherine Woodthorpe AO is an experienced Chair and Non-Executive Director serving for 20 years on the boards of a variety of organizations including listed entities, government boards and for- purpose organisations. Dr. Woodthorpe, amongst several positions, is a Non-Executive Director of the Olivia Newton John Cancer Research Institute, Bioplatforms Australia Ltd. and Vast Solar Pty Ltd. To support the rapid growth and commercialisation of its products the Board has approved the formation of a Clinical Advisory Board and an Energy Advisory Board. These Advisory Boards will comprise initially of two external members and each will be chaired by a member of the AnteoTech Board. Their roles are to advise and support the Company's current and future development. The Advisory Boards will support the AnteoTech Board and senior management in their respective capacities. The Clinical Advisory Board will focus on supporting the development of a pipeline of Point of Care tests using AnteoTech's AnteoBind activated Europium particles combined with its EuGeni reader platform. The Energy Advisory Board will focus on the development, application and commercialisation of AnteoTech's IP in enhancing the energy density of lithium-ion anodes through increased use of silicon. The Advisory Boards will report to the AnteoTech Board acting in an advisory capacity and have no decision authority, or implementation responsibility. The AnteoTech CEO will be joined by the Head of Life Sciences and Head of Energy as ex-officio members of their respective Advisory Boards. Paul Young is Professor of Virology and Head of School (School of Chemistry & Molecular Biosciences) at the University of Queensland, Brisbane, Australia. His current interests are in the molecular virology, diagnosis, vaccine and therapeutic control of dengue and West Nile viruses as well as respiratory syncytial virus and emerging virus infections. He is also investigating the current invasion of the koala genome by a novel retrovirus and its impact on disease in this iconic species. Paul is a past President of the Australian Society for Microbiology, the Australasian Virology Society and the South East Asian Society for Medical Virology. Professor Dominic Dwyer trained in microbiology (virology and infectious diseases) at Westmead Hospital's Institute of Clinical Pathology and Medical Research (ICPMR) in 1986 and became a medical microbiologist in 1997. In 2020 he was selected by the WHO, to be part of a 15 member international team to work with local health officials in Wuhan to explore the origins of the coronavirus. He is currently a Clinical Professor at the University of Sydney's Western Clinical School and recently spent 12 months as a visiting academic in the Service des Maladies Infectieuses et Tropicales at the Hospital Saint-Louis, a public teaching hospital in Paris. Oliver Gross has 20 years' experience in the advanced energy storage industry. He currently holds the position of Walter P. Chrysler Technical Fellow, for Energy Storage Systems, at Stellantis (formally Fiat Chrysler Automobiles), where he is responsible for the Battery systems technology roadmap and architecture. Dr. Kevin Eberman currently provides technical leadership for the development of improved batteries for 3M's line of professional safety equipment and advises on all things battery at 3M.